Fri, Feb 27, 2015, 9:05 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Ampio Pharmaceuticals, Inc. Message Board

racavalli 23 posts  |  Last Activity: Feb 26, 2015 5:52 PM Member since: Jul 31, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • MM promised shareholders last year that if Optina results were bad the company would tell shareholders immediately. If they were good, MM said they would meet with the FDA and shortly after the meeting when they had the FDA guidance, they would advise shareholders.

    Well, the FDA meeting was expected in January and it is no just about March . . . hmmmmmmmmm

    Is there something wrong with this picture?

    Is the company too busy to talk about the Optina results?

    AF is more frequently wrong but this time he is spot on.

    Why is the company delaying or avoiding announcing the Optina results that are far overdue?

  • Reply to

    Results are a Grand Slam.......

    by superforce_57 Feb 25, 2015 8:24 AM
    racavalli racavalli Feb 25, 2015 11:58 AM Flag

    The ambiguities of the WOMAC scale predict declining efficacy as the population numbers increase.

    That is why the American College of Arthritis recommends using the Responder Rate rather than the WOMAC scale.

    It's all in plain sight on the web and just takes a few minutes of your time that will make you a fortune if you just commit a couple of minutes.

    Sentiment: Strong Buy

  • Reply to

    STRUT Phase II efficacy

    by billwilliams836 Feb 25, 2015 10:41 AM
    racavalli racavalli Feb 25, 2015 11:15 AM Flag

    SORRY BILL - YOU ARE ABSOLUTELY 100% WRONG . . . when one realizes the REAL efficacy expressed in the Responder Rate numbers, the outcome is exactly AMAZING.

    You are being misguided by the wrong numbers and should read up on what the American College Of Arthritis recommends to overcome the ambiguities and inaccuracy of the WOMAC scale.

    A paper addressing this subject was published in 2003 and is very clear.

    Sentiment: Strong Buy

  • Reply to

    Don't Be Fooled By Feuerstein Or WOMAC Numbers

    by racavalli Feb 25, 2015 10:21 AM
    racavalli racavalli Feb 25, 2015 10:57 AM Flag

    the womac score at 2 weeks for the 40 patient study was 69% versus a 79% responder rate

    the responder rate is far more accurate and explained in more detail in a the journal of the college of american arthriitis published in 2003

    today's results are being misunderstood by the street but that is not surprising

    big pharma understands the significance of responder rates over womac scale very well and will be motivated to step up their efforts to license ampion sooner than later

    with data this strong, it is to risky to wait any longer so don't be surprised if big pharma liciensing talks heat up very quickly

    Sentiment: Strong Buy

  • Today's results are very strong.

    The Journal of the American College of Arthritis advises that the Responder Rate is far more accurate than the WOMAC scale and today's numbers are more than adequate to cause Big Pharma to line up at Ampio's door to negotiate a deal that will send shares flying.

    Feuerstein is just doing his job for being paid by the hedge funds that are short AMPE. It is obvious that he was ready to pull the trigger on his hit article the moment any good news appeared because he published his BS on The Street minutes after the good news was announced.

    The large funds will understand this and will use this opportunity to increase their positions.

    Sentiment: Strong Buy

  • Reply to

    Adam Fraudstein must have a hit piece out

    by investorgenius Feb 13, 2015 10:12 AM
    racavalli racavalli Feb 13, 2015 11:08 AM Flag

    you know it is coming . . . either from him or from some other paid hit writer for the hedge funds. Just look at the practices of HedgeEye to get an idea of how they influence analyst reports and news to drop prices so they can cover profitably.

    HedgeEye is only one of thousands.

  • racavalli racavalli Feb 13, 2015 11:03 AM Flag

    This is all reported earnings and from conference calls held by the company where they provided guidance.

    All anyone had to do was be on the call.

    Sentiment: Strong Buy

  • racavalli racavalli Feb 13, 2015 10:49 AM Flag

    First two quarters in 2014 were $1,000,000, the third quarter was $6,400,000 and the fourth quarter about to be reported is expected to be $10,000,000.

    This equals over $17,000,000 for 2014.

    Sales are increasing at exponential rates is the reason I am projecting $50,000,000 for 2015.

    Sales will be driven by how quickly the company can fund growth.

    Sentiment: Strong Buy

  • Shares rising on no news. Shorts getting nervous. Volume gradually increasing.

    These are all signs that something very strong and very positive is developing and word is slowly getting out.

    Since results from the 40 patient study are still about a month out and the larger trial even further, we can expect the following:

    Price to continue rising until news comes when shares will explode

    A few hit articles by Adam Feuerstein and others like him who are all paid by hedge funds to create selling to help shorts cover

    Surprise announcements of major proportions regarding Ampion, Optina, cartilage regeneration, Crohn's, COPD, Allergies, Cancer (NCE001) and big pharma licensing agreements. ORP and Zertane both also have the potential to surprise on the upside.

    I'm reiterating my price targets of $50 by July and triple digits by early 2016.

    And . . . when the cartilage news hits, shares will explode beyond ICPT and PBYI and will continue to trade higher.

    Sentiment: Strong Buy

  • 1200% And 2000% Sales Spikes Signal Beginning Of ENORMOUS Growth To Come

    Money talks and BS walks and true numbers that don't lie will soon dictate much higher valuations . . .

    These are real revenues and gross margins are over 90%

    When have you EVER seen growth like this?

    Millennium Healthcare (MHCC) sales:
    2011 - $224,000 Reported
    2012 - $1,686,000 Reported
    2013 - $1,987,000 Reported
    2014 - $17,000,000 - $7.4 million already reported and $10 million within days of reporting final year
    2015 Estimated from pro forma - $50,000,000 plus
    2016 Estimated from pro-forma - $100,000,000 plus

    Shares are EXTREMELY cheap at $.15 (Fifteen cents) but not for long.

    December quarter is close to being announced and earlier indications from company conference call indicated they could be 8 digits which will close 2014 out at $17,000,000 plus.


    12 MONTH PRICE TARGET $3.00+
    24 MONTH PRICE TARGET $10.00+

    Sentiment: Strong Buy

  • This article is such obvious trash and lies that Ampio shares will not be affected because nobody is that stupid to fall for it except the writer and Seeking Alpha.

    Very clumsy attempt by a very bad writer.

    Sentiment: Strong Buy

  • Shares almost always make very large moves before news hits.

    Sellers are exhausted. Shorts are many and nervous. News on Optina could hit any day and it is most likely going to be very positive because the company already told everybody they would only tell shareholders the Optina results if they were bad.

    Ampion is deep into trials and the company could easily surprise.

    We have been repeatedly told that the company is in discussions with big pharma. With the kind of data we have already seen from the safety 7, it would not be a surprise to hear news abut a major licensing deal going down in the next month or two . . . or????

    Meanwhile, enjoy the show.

    I am sticking with my earlier projections of triple digits by the end of 2015 because I am confident it will be demonstrated that Ampion does in fact regenerate cartilage. THERE IS NO OTHER POSSIBLE EXPLANATION FOR THE OVER 90% PAIN REDUCTION 5 MONTHS AFTER THE INJECTIONS. This has never been done before and clearly the value will be unpredictably enormous.

    Again, enjoy a wonderful show for 2015.

    It is highly likely that Fraudstein will try to derail shares when his hedge fund bosses pay him to write another hit article, but he has already lost credibility with AMPE traders and shareholders. Use his articles as a buying opportunity!

    Sentiment: Strong Buy

  • racavalli racavalli Jan 23, 2015 8:18 PM Flag

    Not really. Hedge funds short in large numbers of shares and are in and out in the blink of an eye.

    As the price and volume rises, watch the short position increase as older shorts cover and new shorts establish positions.

    Shorts are actually positive by increasing liquidity.

    They will be overpowered by the big buying as volume swells with big news in the coming months.

    Sentiment: Strong Buy

  • Reply to

    Billoney vs. Facts vs. Optina, who wins?

    by ri66 Jan 22, 2015 9:58 AM
    racavalli racavalli Jan 22, 2015 12:31 PM Flag

    If a reader looks at the mechanism by which Optina works that was clearly explained in Retina Today (Optina actually repairs the F-Actin cortical ring Structure of the cells comprising the linings of the blood vessels) and then reads the simple explanation as to why the trial was halted early . . . and then considers what the company stated in December that they would only release the Optina results if they were bad.. then the reader would quickly call their broker and load up before the explosion. And that does not include any discussion about Ampion.

    I hope hedge funds continue to suppress shares with short selling.

    Sentiment: Strong Buy

  • No news is good news for many reasons. Especially with buying becoming more aggressive.

    We are now in a window of time where AMPE will likely be reporting DAZZLING NEWS.

    This is going to be a fun show especially for all those long-term investors who have made the commitment to ride out the tough times.

    I couldn't help but notice that the message boards are unusually quiet when shares are up on increasing volume.

    Most will call me crazy but I'm sticking with my predictions that AMPE will be a triple digit stock before the end of 2015.

    Sentiment: Strong Buy

  • Get ready for the December quarter results in the next month. They will very likely be even bigger.

    Their model is very simple to understand and they have already implemented enough tests in enough offices to generate HUGE revenues.

    An analysis of the business model indicates that these diagnostics pay for themselves within the first month or two and then become exceptionally profitable thereafter and the growth rate is staggering.

    Everybody has an opinion and certainly has the right to express it, but anybody trying to discredit this company does not know what they are talking about and readers should be very skeptical of these naysayers that will wind up costing fortunes in missed opportunity.

    Sentiment: Strong Buy

  • Reply to

    Playing out exactly as I predicted

    by billf153 Dec 17, 2014 4:06 PM
    racavalli racavalli Dec 18, 2014 12:29 PM Flag

    Large receivables will be flowing in.

    Cash may be tight now, but not for long.

    Shares are remarkably cheap and this is almost the end of tax selling.

    Sentiment: Strong Buy

  • racavalli by racavalli Dec 9, 2014 8:56 AM Flag

    Macaluso said the company would not release the Optina results before the meeting with the FDA which was expected to be in January because of the holidays getting in the way.

    He said, however, that they would release the results to shareholders before the FDA meeting if they were bad.

    We have heard nothing about Optina.

    Does this mean results are positive?

    Sentiment: Strong Buy

  • Reply to

    Listen People

    by gornakhikyan Dec 4, 2014 3:53 PM
    racavalli racavalli Dec 4, 2014 7:42 PM Flag

    You are correct that with sales this strong and knowing that receivables will come in because these diagnostics are reimbursed by Medicare and insurance, funding growth will not be difficult.

    This is one of the least risky stocks I know of with big growth potential because the model and the diagnostics and the sales are already in place. it just gets better with time.

    Sentiment: Strong Buy

  • I would love to be holding a bag full of MHCC shares. When you run the numbers of their projections, and when you compare the September quarter ACTUAL RESULTS, it is clear that this bag full of shares will be worth more than gold in 2015 and beyond.

    Sentiment: Strong Buy

5.64-0.020(-0.35%)Feb 27 4:02 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Opko Health, Inc.
NYSEFri, Feb 27, 2015 4:01 PM EST
Herbalife Ltd.
NYSEFri, Feb 27, 2015 4:01 PM EST